J Clin Endocrinol Metabolism
40.6% of CagriSema patients lost 20% weight compared to 18.3% of those taking semaglutide monotherapy
Medical Writing, Editorial, and Other Assistance Gabrielle Dardis, PhD, and Matt Fitzpatrick, PhD, of RTI Health Solutions, a subsidiary of RTI International, a nonprofit organization that conducts work for government, public, and private organizations, including pharmaceutical companies, provided medical writing support, and John Forbes of RTI Health Solutions provided medical editing support with funding from Bayer AG during manuscript development
The subgroup of patients who adhered perfectly to the semaglutide treatment regimen (i.e., did not discontinue the drug) lost an average of 16.6%